Therapeutics Solutions International Inc., of Oceanside, Calif., said that it plans to license Pan American Cancer Treatment Center four additional immunotherapy products developed by the company, including Cancer Metabolic Detox, Innamune, Lymphoboost, and Memorymune. Read More
Immunogen Inc., of Waltham, Mass., said it intends to offer and sell, subject to market and other conditions, 12 million shares of its common stock in an underwritten public offering and will grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered. Read More
HONG KONG – Preclinical data from a Sino-US study suggest that a tyrosine kinase inhibitor originally developed to treat lymphoma and leukemia, Imbruvica (ibrutinib, Abbvie Inc./Johnson & Johnson), could also target glioma stem cells (GSCs), effectively controlling glioblastoma growth. Read More
In a sign of the times, U.S. lawmakers are recommending that cyberattacks be added to the list of public health threats that the national stockpile and medical countermeasures (MCM) need to address. Read More
LONDON – Just 18 months on from its formation, Microbiotica Ltd. has landed a $534 million deal with Genentech Inc. to apply its microbiome technology in a broad-ranging collaboration in inflammatory bowel disease (IBD). Read More
DUBLIN – A badly bruised Axovant Sciences Ltd. aims to rebuild its pipeline – and its credibility – through a series of deals based on what newly installed CEO Pavan Cheruvu described Wednesday as "a foundation of transformative science." Read More
BOSTON – At a press conference at the BIO International Conference, Alxerion Biotech Inc., a new Massachusetts Institute of Technology (MIT) biotech startup, discussed how it is developing new technologies to harness the therapeutic potential of exosomes, small lipid bilayer vesicles, which are part of the transportable cell secretome. Read More
LONDON – Hookipa Biotech AG agreed to its first major collaboration, forming a potential $400 million-plus partnership with Gilead Sciences Inc. to apply its immunization platform to develop therapies for HIV and hepatitis B infections. Read More
